Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib with nab-paclitaxel and S-1 in locally advanced gastric cancer
NCT04195828Phase 2Completed
- Sponsor
- Fujian Medical University
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in gastric adenocarcinoma, sponsored by Fujian Medical University. Started Jun 2020; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04195828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195828.